About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.440 +0.010 (+0.41%)

Streaming Delayed Price Updated: 9:43 AM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Annovis Bio, Inc. Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Annovis Bio Announces the Filing of a Groundbreaking Patent

June 27, 2023

From Annovis Bio, Inc.

Via Business Wire

Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)

June 20, 2023

From Annovis Bio, Inc.

Via Business Wire

Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update

May 04, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging

April 28, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease

April 11, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

March 23, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)

March 18, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - March 18, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022

March 08, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - March 8, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference

March 03, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease

January 25, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio Enhances Leadership Team with Two Senior Appointments

January 10, 2022

Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice...

Via Newsfile

Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401

January 05, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences

January 03, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - January 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders

December 20, 2021

Berwyn, Pennsylvania--(Newsfile Corp. - December 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage...

Via Newsfile

Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics

December 14, 2021

Berwyn, Pennsylvania--(Newsfile Corp. - December 14, 2021) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference

November 12, 2021

Berwyn, Pennsylvania--(Newsfile Corp. - November 12, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage...

Via Newsfile

Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 09, 2021

Berwyn, Pennsylvania--(Newsfile Corp. - November 9, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage...

Via Newsfile

SHAREHOLDER ALERT: Robbins LLP Investigates Annovis Bio, Inc. (ANVS) for Misleading Shareholders

November 03, 2021

From Robbins LLP

Via Business Wire

Annovis Bio to Present at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 02, 2021

Dr. Maria Maccecchini will present additional Phase 2 data on November 12, 10:25 a.m. ESTA poster highlighting the mechanism of...

Via Newsfile

MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

October 16, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ANNOVIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact the Firm

October 15, 2021

From Bragar Eagel & Squire, P.C.

Via Business Wire

DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

October 14, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

CLASS ACTION UPDATE for ANVS, HNST and HYZN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

October 13, 2021

NEW YORK, NY / ACCESSWIRE / October 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies....

From Levi & Korsinsky, LLP

Via AccessWire

Topics Initial Public Offering Lawsuit

LAWSUITS FILED AGAINST ANVS, EAR and HYZN - Jakubowitz Law Pursues Shareholders Claims

October 13, 2021

NEW YORK, NY / ACCESSWIRE / October 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...

From Jakubowitz Law

Via AccessWire

Topics Fraud Lawsuit

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of LIVE, ANVS and SAVA

October 12, 2021

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies....

From The Gross Law Firm

Via AccessWire

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPLT, ANVS and WDH

October 12, 2021

From The Gross Law Firm

Via AccessWire

Topics Initial Public Offering Lawsuit

MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

October 12, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

MONDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Annovis Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ANVS

October 12, 2021

SAN DIEGO, CA / ACCESSWIRE / October 12, 2021 / Robbins Geller Rudman & Dowd LLP announces that purchasers of Annovis Bio, Inc. (NYSE:ANVS) securities between May 21, 2021 and July 28, 2021, both dates...

From Robbins Geller Rudman & Dowd LLP

Via AccessWire

Topics Lawsuit

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ANVS, VIEW and SESN

October 12, 2021

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to...

From The Klein Law Firm

Via AccessWire

Topics Fraud

LAWSUITS FILED AGAINST ANVS, VIEW and WDH - Jakubowitz Law Pursues Shareholders Claims

October 12, 2021

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...

From Jakubowitz Law

Via AccessWire

Topics Fraud Initial Public Offering Lawsuit

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Annovis Bio, Inc. Common Stock (NY:ANVS)

Press Releases about Annovis Bio, Inc. Common Stock

Sections

Services

Contact Information

Follow Us